Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020
Palma, Spain and San Diego, USA, October 12, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, announced that it will present new data on its lead asset SNF472 at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting on October 22, 2020. Sanifit will make four presentations including one oral session and three ePoster sessions.
- New data from the randomized placebo-controlled study CaLIPSO will describe consistent effect of SNF472 in slowing progression of coronary arterial calcification in ESKD patients on hemodialysis across key subgroups.
- New analysis of the data from CaLIPSO will show exposure-efficacy relationship between the agent and progression of coronary calcification.
- Design of the recently initiated phase 3 study in calciphylaxis (CALCIPHYX).
- Preclinical data evaluating inhibition of valvular calcification in porcine valve leaflets.
The meeting will run from October 22-25 2020 and will be fully virtual, with further information available on the ASN website. Full details of the abstracts are as follows:
Oral Presentation:
Title: SNF472 Consistently Slows Progression of Coronary Artery Calcification Across Subgroups of Patients on Hemodialysis
Date & Time: Thursday, October 22, from 17.00-19.00 p.m. EDT
Presentation Code: OR0401
Link to Abstract.
ePoster Sessions:
Title: Design of the CALCIPHYX Study, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SNF472 for Treating Calciphylaxis
Date & Time: Thursday, October 22, 10:00 a.m. EDT
ePoster Code: INFO07
Link to Abstract.
Title: PK-PD and exposure-efficacy evaluation from CaLIPSO, a phase 2B study to assess the effect of SNF472 on progression of cardiovascular calcification in patients on hemodialysis
Date & Time: Thursday, October 22, 10:00 a.m. EDT
ePoster Code: PO1142
Link to Abstract.
Title: SNF472 inhibits heart valve calcification in a novel in vitro method using porcine whole leaflets
Date & Time: Thursday, October 22, 10:00 a.m. EDT
ePoster Code: PO0320
Link to Abstract.
-ENDS-
For further enquiries:
Sanifit
Joan Perelló, CEO
Adam Levy, CFO
For media enquiries:
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Sarah Wilson
Tel: +44 (0) 20 3709 5700
Email: sanifit@consilum-comms.com
About Sanifit
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. The company’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study among hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease in end-stage kidney disease patients as a second indication for SNF 472. For more information, please visit www.sanifit.com.